<DOC>
	<DOCNO>NCT00583765</DOCNO>
	<brief_summary>Dialysis require thin blood prevent clot dialysis machine . Thinning blood necessary form blood thinner may cause bleeding . Therefore , researcher seek way minimize bleed risk ensure effective dialysis . One medication use thin blood dialysis machine citrate . Citrate advantage blood-thinning property quickly reverse calcium patient 's blood . As consequence , blood machine thin , greatly reduce risk bleed dialysis carry use blood thinner . Until , patient receive citrate dialysis administer citrate separate infusion IV pump dialysis machine . This method require complex monitoring calculation . This study Prismocitrate dialysis fluid similar regular dialysis fluid use intensive care unit , except fluid already contain exactly correct amount citrate . Thus , method require separate pump citrate calculation pump citrate blood go kidney machine . Having citrate already contain dialysis fluid simplifies procedure reduces possibility calculation error . This study seek determine simplify mean provide blood thin kidney machine also result correct balance blood salt .</brief_summary>
	<brief_title>Evaluation Simplified Protocol Regional Citrate Anticoagulation Continuous Venovenous Hemodiafiltration</brief_title>
	<detailed_description>Acute renal failure common among critically ill [ 1-3 ] , independent contributor morbidity mortality [ 4,5 ] . Continuous renal replacement therapy ( CRRT ) commonly use renal replacement group . This require extracorporeal circuit , maintenance require anticoagulation . Heparin common anticoagulant use CRRT . However , heparin exposure CRRT major risk surgery trauma . Citrate use regional anticoagulant plasmapheresis chronic dialysis many year [ 12,13 ] , increasingly use CRRT . Regional anticoagulation refers provision anticoagulation within extracorporeal circuit without alteration coagulation patient 's systemic circulation . Calcium co-factor coagulation . Citrate reduces level ionize calcium blood extracorporeal circuit level coagulation occur . Once blood return patient 's systemic circulation , calcium level restore coagulation occur . Renal replacement solution CRRT use citrate anticoagulation , calcium-free . [ 14-19 ] Despite reduce risk bleeding , widespread adoption citrate regional anticoagulation limit lack commercially available calcium-free solution complexity many protocol . Part complexity requirement separate citrate infusion extracorporeal circuit achieve regional anticoagulation . This simplified protocol provide citrate replacement fluid infuse prefilter anticoagulant buffer . To predict appropriate replacement rate , Hospal Gambro scientific laboratory develop calculation model predict physiological interaction component administer replacement- hemodialysis fluid patient 's complex metabolic system . These interaction influence , large part , systemic parameter blood-flow ultrafiltration rate , patient parameter , acid base-status liver function . This calculation model need clinical validation respect ability predict outcome narrow margin metabolic disturbance cause administration citrate anticoagulation . A previous study similar replacement fluid use citrate 8 mmol/L citric acid 4 mmol/L result mild metabolic acidosis minimal clinical significance subject study evaluate modify version fluid contain citrate 10 mmol/L citric acid 2 mmol/L calculate provide optimal metabolic balance . Subjects : Twenty patient General Systems ICU University Alberta Hospital treat CVVHDF use Prisma-CFM machine study . Inclusion criterion : 1 . Male female 17 80 year age . 2 . Intensive care unit patient . 3 . Renal failure require CVVHDF . 4 . Likely survive least 72 hour . Exclusion criteria 1 . Age &gt; 80 year 2 . Need systemic anticoagulation , fibrinolytic therapy activate protein C 3 . Acute chronic hepatic failure Patients treat regular CVVHDF set pre-dilution mode . The replacement flow-rate citrate replacement fluid depend blood pump speed [ fix ratio , see 9.3 table ] . Mean dialysate flow 100 ml/hr 2500ml/hour accordance desire base-equivalent intake . Access pressure keep -100 150mmHg . Access return pressure monitor . Specially formulate replacement- dialysate fluid use . Citrate anticoagulation Published literature data show mean citrate-dosage 3.5 4mmol/l undiluted blood necessary decrease level ionize serum calcium 0.4mmol/l provide sufficient anticoagulation maintain extracorporeal circuit . A minimum citrate concentration 3.5 mmol/l blood use protocol . The infused citrate replacement fluid contain trisodium citrate citric acid mixture ( 10mmol/l tri-sodium citrate plus 2 mmol/l citric acid ) . Preliminary result prove anticoagulation potency mixture similar plain 12 mmol/l tri-sodium citrate solution . Therefore fix ratio citrate replacement fluid infuse pre-pump predilution mode per 1 liter effective blood flow . Calcium replacement : The loss calcium- magnesium-citrate ultra-filtrate via hemofilter need compensate avoid systemic hypocalcemia hypomagnesemia . Calcium replacement solution prepare remove 300 mls 1000 ml bag 0.9 % saline subsequently add 200 mls 10 % calcium gluconate bag . This calcium gluconate solution infuse via central line initial infusion rate 60 ml/hr . Ionized calcium level monitor every 6-8 hour correct change flow rate infusion . Potassium replacement : Potassium add replacement dialysate fluid base clinical requirement . Sodium-bicarbonate adjustment : The sodium bicarbonate level influence flow-rate replacement fluid ( citrate intake ) dialysate flow ( bicarbonate intake ) . It monitor every 6 hour correct treatment alter dialysate flow . Reducing flow rate lower bicarbonate intake case metabolic alkalosis , raise flow increase bicarbonate intake case metabolic acidosis . If adjustment successful , correction do add bicarbonate next dialysate fluid bag , change : Consent procedure Subjects identify , recruit informed consent obtain principal investigator , co-investigator research co-ordinators . Study benefit The study renal replacement solution include element require safe use . It require custom preparation hospital personnel . This minimize risk error increase patient safety . It hop study eventually enable general use simple safe technique citrate regional anticoagulation continuous renal replacement therapy . Adverse effect CVVHDF use citrate regional anticoagulation use protocol may associate hypocalcemia , metabolic alkalosis acidosis , hypernatremia hyponatremia . In anticipation , protocols include one use extensive metabolic monitoring algorithmic response abnormality . This simplify protocol minimize potential complication . Adverse effect would notify patient family , investigator , HREB committee . Privacy Patient data anonymized prevent identification . Gambro Canada ( study sponsor ) access anonymized case report form aggregate report .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Dialysis Solutions</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Male female 17 80 year age . Intensive care unit patient . Acute renal failure require continuous venovenous hemodiafiltration . Likely survive least 72 hour Age &gt; 80 year Need systemic anticoagulation , fibrinolytic therapy activate protein C Acute chronic hepatic failure</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Kidney Failure , Acute</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Hemofiltration</keyword>
	<keyword>Anticoagulation</keyword>
	<keyword>Citrate</keyword>
</DOC>